Search clinical trials for: Safinamide Mesilate

Total 1417 results

Eisai Korea Inc.

Completed

A Study to Evaluate the Efficacy and Safety of Safinamide Mesilate as Add-on Therapy to Levodopa in Parkinson's Disease Participants With Motor Fluctuation in South Korea

Parkinson Disease

Korea, Republic of
Zambon SpA

Completed

A Single and Multiple Dose Study to Assess How the Drug Enters, Moves Through and Exits the Body, Safety and Tolerability of Safinamide in Healthy Adult Chinese Volunteers

Healthy

China
Zambon SpA

Completed

Safinamide for Multiple System Atrophy (MSA)

Multiple System Atrophy

Italy, Spain
Zambon SpA

Withdrawn

Safinamide for Levodopa-induced Dyskinesia (PD-LID)

Parkinson Disease | Dyskinesia, Drug-Induced
Alain Kaelin
Clinical Trial Unit Ente Ospedaliero Cantonale

Recruiting

Effect of Safinamide on Sleep Quality in Patients With Parkinson's Disease

Idiopathic Parkinson's Disease (at Later Stage)

Switzerland
Newron Pharmaceuticals SPA

Completed

Safinamide Renal Impairment Trial

Renal Impairment

Germany
Supernus Pharmaceuticals, Inc.

Completed

Clinical Outcome Assessment of Parkinson's Disease Patients Treated With XADAGO (Safinamide) (PRO-Go)

Idiopathic Parkinson Disease

United States
Zambon SpA

Completed

Effect of Safinamide on Parkinson's Disease Related Chronic Pain

Idiopathic Parkinson Disease

Spain, Austria, Italy, Germany, France
Newron Pharmaceuticals SPA

Completed

Safinamide as Add-On Therapy in Patients With Early Idiopathic Parkinson's Disease Treated With a Stable Dose of a Single Dopamine Agonist (12 Month Extension)

Parkinson's Disease
Eisai Limited

Completed

An Open-label, Multicenter, Multiple Dose, Phase 1 Study to Establish the Maximum Tolerated Dose of E7389 Liposomal Formulation in Patients With Solid Tumors

Solid Tumors

United Kingdom
Newron Pharmaceuticals SPA

Terminated

Open-Label Trial to Determine the Long-Term Safety of Safinamide in Parkinson's Disease Patients

Parkinson's Disease

Romania
Newron Pharmaceuticals SPA

Completed

A Study to Assess the Effect of Hepatic Impairment on Safinamide Pharmacokinetics

Hepatic Impairment

Germany
Newron Pharmaceuticals SPA

Completed

Safinamide as Add-On Therapy in Patients With Early Idiopathic Parkinson's Disease Treated With a Stable Dose of a Single Dopamine Agonist

Idiopathic Parkinson's Disease
Newron Pharmaceuticals SPA

Completed

A Trial to Explore the Potential Benefit of Safinamide on Cognitive Impairment Associated With Parkinson's Disease

Parkinson's Disease With Cognitive Impairments

Spain, United States
Newron Pharmaceuticals SPA

Terminated

A Study to Evaluate Safinamide's Effect on Dopamine and Serotonin's Availability by Using Brain Imaging

Parkinson Disease

United States
Zambon SpA

Completed

A Study to Evaluate the Efficacy and Safety of Safinamide, as add-on Therapy, in Idiopathic Chinese Parkinson's Disease (PD) Patients With Motor Fluctuations Treated With Stable Doses of Levodopa

Parkinson Disease

China
Newron Pharmaceuticals SPA

Completed

18-month Study of Long-term Efficacy & Safety of Safinamide as add-on Therapy in Patients With Mid-late Stage PD

Parkinson's Disease
IRCCS San Raffaele Roma

Completed

Overnight Switch From Rasagiline To Safinamide (SWH-MAOB)

Parkinson Disease

Italy
Newron Pharmaceuticals SPA
Parexel; CliniRx

Completed

Efficacy and Safety of Ralfinamide in Patients With Chronic Neuropathic Low Back Pain

Pain

United Kingdom
Newron Pharmaceuticals SPA

Completed

Phase II Dose Titration Study in Patients With Neuropathic Pain

Neuropathic Pain

United Kingdom, Czech Republic, Poland, Italy, India, Austria
Newron Pharmaceuticals SPA

Completed

Safinamide in Levodopa Induced Dyskinesia in Parkinson's Disease Subjects (Safinamide-LID)

Parkinson's Disease

Austria, Canada, France, Germany, South Africa
Newron Pharmaceuticals SPA

Completed

Efficacy and Safety of Safinamide (50 and 100mg/Day) Versus Placebo, in Patients With Mid-late Stage Parkinson's Disease

Parkinson's Disease
Newron Pharmaceuticals SPA

Terminated

MOTION, Safinamide in Early Idiopathic Parkinson's Disease (IPD), as add-on to Dopamine Agonist (Extension of Trial 27918) (MOTION)

Idiopathic Parkinson's Disease

Switzerland
Universita di Verona
Azienda Ospedaliera Universitaria Integrata Verona

Unknown

Pain in Parkinson's Disease With Motor Fluctuations. (PAINinPD)

Parkinson Disease

Italy
University of Bologna

Completed

Exploratory Study of IMATINIB High Dose in Intermediate Risk Chronic Myeloid Leukemia in Chronic Phase

Myeloid Leukemia, Chronic, Chronic-Phase

Italy
Novartis Pharmaceuticals

Completed

Imatinib Mesylate in Patients With Refractory Desmoplastic Small Round Cell Tumors

Refractory Desmoplastic Small Round Cell Tumors

Italy
Eisai Limited

Completed

A Placebo-Controlled, Double-Blind Comparative Study of E2080 in Lennox-Gastaut Syndrome Patients (Study E2080-J081-304)

Lennox-Gastaut Syndrome

Japan
Wuhan Union Hospital, China

Completed

Pharmacokinetics and Tolerability of Rufinamide in Healthy Chinese Subjects

Seizures
Chengdu Zenitar Biomedical Technology Co., Ltd

Completed

Study of Prilinostat Mesylate for Injection in the Treatment of Relapsed or Refractory B Cell-related Tumor-predominant

Diffuse Large B Cell Lymphoma，DLBCL

China
Centre Leon Berard

Completed

Efficiency of Imatinib Treatment Maintenance or Interruption After 3 Years of Adjuvant Treatment in Patients With Gastrointestinal Stromal Tumours (GIST) (ImadGist)

Gastrointestinal Stromal Tumors | Resected Gastrointestinal Stromal Tumors | Non-metastatic | High Risk of Recurrence | KIT Gene Mutation

France
Swiss Group for Clinical Cancer Research

Terminated

Eribulin as 1st Line Treatment in Elderly Patients With Advanced Breast Cancer

Adenocarcinoma | Breast Cancer

Switzerland
Tianjin Chasesun Pharmaceutical Co., LTD
Southwest Hospital, China

Completed

Phase I Study of Kukoamine B Mesilate in Healthy Volunteers

Healthy

China
Cancer Research UK
Latus Therapeutics

Terminated

A Trial Looking at the Use of Camostat in People Who Have Tested Positive for Coronavirus (COVID-19) (SPIKE-1) (SPIKE-1)

COVID-19 Infection

United Kingdom
IlDong Pharmaceutical Co Ltd

Completed

A Phase I Study of IDP-73152 Mesylate in Health Male Volunteer (PDF inhibitor)

Healthy

Korea, Republic of
Newron Pharmaceuticals SPA

Completed

Safinamide in Idiopathic Parkinson's Disease (IPD) With Motor Fluctuations, as add-on to Levodopa (SETTLE)

Idiopathic Parkinson's Disease

Korea, Republic of, Israel, Thailand, New Zealand, Spain, Canada, United States, Switzerland, Netherlands, Taiwan, United Kingdom, Belgium, Estonia, Germany, Hungary, India, Australia, Austria, France, Malaysia, Slovakia
Sagent Pharmaceuticals Inc.

Completed

Camostat Efficacy vs. Placebo for Outpatient Treatment of COVID-19 (CAMELOT)

COVID-19

United States
Yale University

Completed

Camostat Mesylate in COVID-19 Outpatients

COVID-19

United States
Tianjin Chasesun Pharmaceutical Co., LTD
Southwest Hospital, China

Completed

Study of Multiple-dose Kukoamine B Mesilate in Healthy Volunteers

Healthy

China
Eisai Inc.

Completed

Compassionate Use of Eribulin for the Treatment of Advanced Breast Cancer Refractory to All Other Marketed Therapies

Breast Cancer

United States
Eisai Co., Ltd.

Completed

Study of E7389 for Advanced or Metastatic Breast Cancer

Breast Cancer

Japan
Calgent Biotechnology Co., Ltd

Completed

Safety, Tolerability, and Pharmacokinetics of CAL056 Mesylate in Patients With Resistant or Refractory Solid Tumors

Resistant or Refractory Solid Tumors

United States, Taiwan
Eisai Korea Inc.

Completed

Eribulin Mesylate Phase IV Clinical Trial in Korean Patients With Metastatic or Locally Advanced Breast Cancer (ESKIMO)

Breast Cancer | Breast Neoplasms

Korea, Republic of
Eisai Inc.

Approved for marketing

An Open-Label, Multi-Center, Expanded Access Program With Eribulin for the Treatment of Advanced Breast Cancer Refractory

Metastatic Breast Cancer

Canada, Belgium, France
Merz Pharmaceuticals GmbH

Terminated

Open-Label, Long-Term Treatment Study, to Assess the Long-Term Safety and Tolerability and Efficacy of Neramexane in Patients With Subjective Tinnitus (OLLTT)

Subjective Tinnitus

United States, United Kingdom, Poland, Austria, Belgium, Brazil, Czech Republic, France, Germany, Mexico, Netherlands, Portugal, South Africa, Spain
Pathway Therapeutics, Inc.

Completed

Study of PWT33597 Mesylate in Subjects With Advanced Malignancies

Malignancies

United States
Merz Pharmaceuticals GmbH

Terminated

Open-lable Extension Study on Safety and Efficacy of Neramexane to Treat Congenital and Acquired Nystagmus

Multiple Sclerosis | Nystagmus, Congenital | Nystagmus, Acquired

United Kingdom
Merz Pharmaceuticals GmbH

Completed

Investigate the Effect of Neramexane Mesylate IR Tablet on Driving Fitness and Capability to Operate Machines in Healthy Volunteers

Healthy

Germany
Nanjing First Hospital, Nanjing Medical University

Enrolling by invitation

Mid-and Long-term Efficacy of Ergot Alkaloids in the Treatment of Salivation in Patients With Parkinson's Disease.

Main Heading (Descriptor) Terms

China
Eisai Limited

Completed

QT Interval Prolongation Study of Eribulin Mesylate (E7389) in Patients With Advanced Solid Tumors

Advanced Solid Tumor

France
Newron Pharmaceuticals SPA

Completed

A Study to Assess the Effect of Safinamide on Levodopa Pharmacokinetics

Idiopathic Parkinson's Disease

Italy

3

Subscribe